Heighten Science Publications Inc.

Triple Negative Breast Cancer Insights from a Two Year Study at CHSF on Early Stage Management and Oncogenetic Evolution

—

by

Vishnu
in

Introduction

Triple negative breast cancer (TNBC) remains one of the most challenging breast cancer subtypes due to its aggressive nature and lack of targeted therapies. A recent study conducted over two years at the Centre Hospitalier Sud Francilien (CHSF) sheds new light on how early-stage TNBC patients are diagnosed, managed, and followed-up, especially with an emphasis on oncogenetic evolution.
Visit https://www.obstetricgynecoljournal.com for more groundbreaking research in this field.

Study Highlights & Key Findings

  • TNBC accounted for 10% of breast cancer cases treated at CHSF.
  • Most affected age group: 50–60 years, average age 56.68.
  • 61.29% had normal BMI, and 70.96% were postmenopausal.
  • 48.38% were pauciparous, and 64.51% had breastfed.

Clinical and Diagnostic Characteristics

  • 96.77% of patients sought medical care within 3 months of symptoms.
  • Most tumors measured ≥30 mm at diagnosis.
  • The upper-outer quadrant of the breast was most frequently affected.
  • 58.06% had adenopathies at diagnosis; 93.54% had infiltrating ductal carcinoma.
  • 83.87% of tumors were Grade III with high Ki-67 index (up to 100%).

Treatment Modalities

  • Neoadjuvant chemotherapy for tumors ≥30 mm.
  • Mastectomy performed in 45.16% of patients.
  • Breast reconstruction offered to 21.42% of mastectomy patients.
  • Postoperative radiotherapy in 96.66% of cases.

Oncogenetic Survey & Immunotherapy

  • 11 patients underwent genetic screening using Manchester criteria.
  • Two BRCA1 and one BRCA2 mutations were detected.
  • Patients with BRCA mutations were recommended for prophylactic mastectomy and adnexectomy by age 40.
  • Two patients received immunotherapy (atezolizumab + abraxane) for recurrence based on PD-L1 positivity.

Broader Implications from External Sources

According to the American Society of Clinical Oncology (ASCO), TNBC demands tailored therapies beyond traditional chemotherapy. The study aligns with ASCO’s emphasis on integrating genomic testing and immunotherapy for better patient outcomes.

Further Reading and Resource

Call-to-Action

Explore more studies at https://www.obstetricgynecoljournal.com and join the conversation by sharing your thoughts in the comments below!

Disclaimer: This content is generated using AI assistance and should be reviewed for accuracy and compliance before considering this article and its contents as a reference. Any mishaps or grievances raised due to the reusing of this material will not be handled by the author of this article.

Comments

Leave a comment